Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226172 · ClinicalTrials.gov registry record · Phase 2
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT02226172 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 21 participants.
The verdict
NCT02226172, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
A lead-in cohort of \~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to ruxolitinib.
Interventions
- DRUG Placebo
- DRUG Glasdegib (PF-04449913)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-10-06 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02226172
The ClinicalTrials.gov registry entry for NCT02226172 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02226172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02226172 about?
NCT02226172 is a clinical study titled "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib". A lead-in cohort of \~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent...
What is the current status of trial NCT02226172?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2014-10-06. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT02226172?
The interventions under investigation include: Placebo (DRUG), Glasdegib (PF-04449913) (DRUG).
Who is sponsoring clinical trial NCT02226172?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.